KRAS and neoplasm: Since KRAS mutations are known to constitutively activate the AKT/mTOR pathway through its effector proteins [41], it is reasonable to assume that the presence of a high pCASTOR1 score in LUAD with KRAS mutations is indicative of a dysregulated mTORC1 activity, and hence more aggressive tumor growth and worse patient survival.